Pages that link to "Q34446380"
Jump to navigation
Jump to search
The following pages link to A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance (Q34446380):
Displaying 8 items.
- Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma (Q33490314) (← links)
- Oral epithelial stem cells - implications in normal development and cancer metastasis (Q34147649) (← links)
- Molecular pathways: regulation and therapeutic implications of multidrug resistance (Q34255292) (← links)
- L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity. (Q35024848) (← links)
- Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor (Q36788463) (← links)
- Recent progress in tumor pH targeting nanotechnology (Q37197375) (← links)
- The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system (Q37403035) (← links)
- Development of stealth liposome coencapsulating doxorubicin and fluoxetine (Q39608885) (← links)